VASCULITIS CLINICAL RESEARCH CONSORTIUM (VCRC) STUDY OF WEGENER'S GRANULOMATO

血管炎临床研究联盟 (VCRC) 对韦格纳肉芽肿的研究

• 批准号: 7608200
• 负责人: Carol Langford
• 金额: $ 0.45万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7608200
• 关键词: Biological Markers; Blood; Clinical; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Disease; Funding; Gene Proteins; Grant; Institution; Laboratory Research; Methods; Patients; Persons; Physicians; Purpose; Research; Research Personnel; Resources; Source; Specimen; Time; United States National Institutes of Health; Urine; Vasculitis; information gathering

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. It is often very difficult for both patients and physicians to determine how "active" a person's vasculitis is at any given time, yet it is critically important to determine disease activity in order to properly treat these diseases. The purpose of these studies is to use new scientific methods to discover biological markers of disease activity in patients with vasculitis. This will hopefully be accomplished by gathering information from blood and urine specimens and correlating this to clinical disease. The blood and urine specimens will be sent to research laboratories that will be looking to discover new proteins, genes, and other factors that could serve as new "biomarkers."

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 患者和医生通常很难在任何给定时间确定一个人的血管炎有多“活跃”，但确定疾病活动性以正确治疗这些疾病至关重要。 这些研究的目的是使用新的科学方法来发现血管炎患者疾病活动的生物标志物。 这将有望通过从血液和尿液样本中收集信息并将其与临床疾病相关联来实现。 血液和尿液样本将被送往研究实验室，这些实验室将寻找新的蛋白质、基因和其他可以作为新的“生物标志物”的因素。"